Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization

Tevogen Bio Holdings Inc.

Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.
Shareholders authorized reverse stock split at ratio between 1:25 and 1:85, with exact ratio set by Board in its discretion.
Both proposals passed with strong support: 147.8M for plan amendment; 176.3M for reverse split (no broker non-votes on split).
182.4 million shares were represented at the special meeting, ~90.5% of outstanding 201.5M shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.